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Abstract
Purpose of Review—The purpose of this review is to provide an overview of dietary 
phosphorus, its sources, recommended intakes, and its absorption and metabolism in health and in 
chronic kidney disease, and to discuss recent findings in this area with a focus on the effects of 
inorganic phosphate additives in bone health.
Recent Findings—Recent findings show that increasing dietary phosphorus through inorganic 
phosphate additives has detrimental effects on bone and mineral metabolism in humans and 
animals. There is new data supporting an educational intervention to limit phosphate additives in 
patients with chronic kidney disease to control serum phosphate.
Summary—The average intake of phosphorus in the US well-above the recommended dietary 
allowance. Inorganic phosphate additives, which are absorbed at a high rate, account for a 
substantial and likely underestimated portion of this excessive intake. These additives have 
negative effects on bone metabolism, and present a prime opportunity to lower total phosphorus 
intake in the U.S. Further evidence is needed to confirm whether lowering dietary phosphorus 
intake would have beneficial effects to improve fracture risk.
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Introduction
Phosphorus is an important nutrient for bone health, but intakes in the U.S. usually well-
exceed requirements. This is problematic because excessive dietary phosphorus has been 
associated with adverse effects on bone and mineral metabolism. New literature in this area 
highlights the effects of a high dietary phosphorus burden from prevalent use of phosphate-
based food additives in the U.S. This review provides an overview of the role of phosphorus 
in bone health, adverse effects of excess intake, and findings from recent studies focused on 
effects of phosphate additives on bone and mineral metabolism in health, and in the special 
case of chronic kidney disease-mineral bone disorder.
Phosphorus as an Essential Nutrient
Phosphorus is an essential nutrient in human health and has a variety of physiological roles. 
These include structural roles, as phosphorous is a major component of cell membranes (i.e. 
phospholipid bilayer), the sugar-phosphate backbone of nucleic acids, and hydroxyapatite 
(Ca10(PO4)6(OH)2) in bones and teeth. Additionally, phosphorus plays important roles in 
energy metabolism (e.g. in ATP, GTP, ADP, GDP), in acid/base balance, and in intracellular 
cell signaling (1). The vast majority of the body’s phosphorus is found in bone mineral 
(approximately 85%), and the remaining 15% is distributed in soft tissues with about 1% in 
extracellular fluid (2). Phosphorus deficiency results in rickets and stunted growth in 
children and osteomalcia in adults. However, dietary phosphorus deficiency is very rare in 
humans, due to the natural ubiquity of phosphorus in a large array of foods and our high 
capacity to absorb it. Only in special circumstances, such as starvation, refeeding syndrome, 
or poorly managed parenteral nutrition is hypophosphatemia observed in otherwise healthy 
individuals (1). Thus, most cases of phosphorus deficiency result from a defect in renal 
reabsorption of phosphate. There are a variety of renal hypophosphatemias that are 
characterized by a low plasma phosphate and a low tubular maximum reabsorption rate of 
phosphate (TmP). These include genetic disorders that cause either highly increased levels 
of the phosphaturic hormones, fibroblast growth factor-23 (FGF23) or parathyroid hormone 
(PTH), or cause defects in the renal tubular sodium phosphate co-transporters that are 
responsible for phosphate reabsorption (3). Oral phosphate supplements are needed as part 
of treatment for these patients. Outside of these specific patient groups, humans are usually 
able to easily consume adequate phosphorus from a variety of foods.
Dietary Phosphorus Intake and Sources
The most recent Dietary Reference Intakes (DRIs) for phosphorus in the United States were 
established by the Institute of Medicine in 1997 (1). These include the estimated average 
requirement (EAR), the intake level estimated to meet the needs of 50% of healthy 
individuals in a group (age/sex/life stage), and the recommended dietary allowance (RDA), 
the intake level estimated to meet the requirements of 97.5% of healthy individuals in a 
group. Phosphorus is present in foods in naturally-occurring forms in meats, nuts, seeds, 
legumes, dairy foods, and grains, as well as in inorganic phosphate additives that are used 
for a variety of purposes in food processing. Because phosphorus is so widespread in the 
food supply both naturally and from additives, most people do not have difficulty meeting 
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intake requirements and dietary phosphorus deficiency is extremely rare. Instead, usual 
dietary intakes generally well-exceed recommended intakes. Data from the National Health 
and Nutrition Examination Survey (NHANES) 2005–2006 show that this is true for males 
and females across all age groups, except for adolescent women ages 9–18 years old, whose 
average intake is similar to the EAR (4). In healthy adults, the phosphorus EAR is 580 mg/d 
and the RDA is 700 mg/d (1). However, the average phosphorus intake of U.S. adults over 
the age of 20 is 1399 mg/d – approximately 2.5 times the EAR and twice the RDA. McClure 
et al. (5) recently described the trends in dietary phosphorus intake in U.S. adults between 
2001–2014 from NHANES data, as well as the percent contributions of various categories of 
foods to total phosphorus consumption. Although total phosphorus consumption has risen 
over the recent decades (6), intakes were relatively stable between 2001 and 2014 (5). Grains 
were the largest contributor to total dietary phosphorus intake, accounting for 29.3% of 
intake. Other major contributors were milk and milk products (21% of intake) and meat, 
poultry, fish and mixtures (25% of intake). Despite being considered somewhat of a villain 
in the phosphorus world, soft drinks contributed only 3.3% to total phosphorus intakes. 
However, unlike foods like grains, dairy and meats, soft drinks usually provide minimal to 
no additional nutrients aside from calories and sugar (7). Further, consumption of cola, in 
particular, is associated with altered bone metabolism, low bone density and fracture in 
human and animal studies (8–14).
Bioavailability of phosphorus also varies depending on source. Plant protein sources 
generally have the lowest bioavailability, followed by animal protein sources, then inorganic 
phosphate additives with the highest bioavailability. Inorganic phosphates have been 
considered to be nearly 100% bioavailable. However, this might be better described as 
nearly 100% bioaccessible (i.e. what is available for absorption), rather than bioavailable 
(i.e. what is absorbed and available to the tissues) (15). Scanni et al. (16) showed in healthy 
adults that only 73% of inorganic phosphate infused by nasoduodenal feeding tube was 
recovered in the urine, compared with 100% of i.v.-infused phosphate. This suggests only 
73% of the inorganic phosphate infused into the duodenum was absorbed, despite that the 
bioaccessibility of sodium phosphate is ~100%. St-Jules et al. (17) further demonstrate the 
case for less than 100% bioavailability of inorganic phosphate by highlighting the 
discrepancy between the proportion of phosphorus excreted in the urine versus the amount 
of phosphate given in multiple human feeding studies.
Regulation of Phosphorus Homeostasis
Phosphorus homeostasis is maintained via a multi-tissue axis involving the kidneys, 
parathyroid glands, intestine, and bone. The three main hormones responsible for 
phosphorus homeostasis are PTH, FGF23, and 1,25-dihydroxyvitamin D (1,25D) (18). The 
normal range of serum phosphate is 2.5–4.5 mg/dL. Transient elevations in serum phosphate 
cause increased PTH production and secretion, which increases the conversion of 25-
hydroxyvitamin D to 1,25D via the renal CYP27B1 (1α-hydroxylase) enzyme. Both PTH 
and 1,25D stimulate FGF23 production from osteocytes. PTH and FGF23 increase urinary 
phosphate excretion by inhibiting the renal sodium-phosphate co-transporters (NaPi-2a and 
NaPi-2c) which results in decreased renal phosphate reabsorption. PTH and 1,25D stimulate 
bone resorption to release calcium and phosphorus, and 1,25D increases the active 
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absorption of both calcium and phosphorus from the intestine. Homeostasis is further 
maintained by negative feedback loops involving these three hormones: FGF23 provides 
negative feedback on PTH and 1,25D, and 1,25D provides negative feedback on itself and 
PTH.
Intestinal absorption of dietary phosphorus occurs by both transcellular active transport that 
is sodium dependent, and paracellular passive transport that is sodium-independent. The 
major known phosphate transporter in the intestine brush border membrane is sodium-
phosphate co-transporter 2b (NaPi-2b), which is a type II sodium-phosphate transporter that 
shares homology with NaPi-2a and NaPi-2c in the kidney (19, 20). In addition to high levels 
of phosphorus present in our foods, humans also have generally high phosphorus absorption 
efficiency, around 60–70 % from a typical mixed diet (21). The major known modulators of 
phosphorus absorption efficiency are dietary phosphorus, 1,25D, and FGF23. Low 
phosphorus diets and 1,25D directly increase phosphorus absorption efficiency, while 
FGF23 decreases phosphorus absorption efficiency indirectly through its inhibition of 1,25D 
(21, 22). It had been presumed that the effect of low phosphorus diets on increased intestinal 
phosphorus absorption was mediated by an increase in 1,25D (21, 23). However, low 
phosphorus diets cause increased intestinal phosphorus absorption even in VDR and 
CYP27B1 knockout mice (24, 25). This suggests that the effects of low phosphorus diets on 
increased phosphorus absorption are vitamin D-independent and through mechanisms not 
yet fully known. Low phosphorus diets and 1,25D both increase NaPi-2b abundance in the 
brush border membrane. But, low phosphorus diets appear to affect NaPi-2b through both 
transcription and post-transcriptional mechanisms, whereas the effects of 1,25D appear to be 
post-transcriptionally mediated (21).
Despite the role of the intestine in absorbing phosphorus, thus making it bioavailable for its 
many physiological functions, the kidney is the main point of regulation of serum phosphate 
(26, 27). Scanni et al. (16) recently demonstrated in healthy adults the kidneys’ ability to 
fully compensate for increased absorbed phosphorus load, and that the intestine did not play 
a noticeable role in this response. However, even if renal phosphate excretion is able to 
maintain phosphate balance and serum phosphate within normal range, adverse effects of 
high dietary phosphorus on bone and mineral metabolism are still present.
High Dietary Phosphorus Intake Effects on Bone Health
Early studies in animals show that high dietary phosphorus, particularly with low dietary 
calcium, reduces bone mass, and that this is mediated by secondary hyperparathyroidism 
(28–31). Draper et al. (30) demonstrated that parathyroidectomy prevented increased bone 
resorption in response to a high phosphorus diet in adult rats. More recently, the bone matrix 
protein osteopontin (OPN) has been identified as another factor that mediates the increased 
bone resorption response to a to high phosphorus diet. Koyama et al. (32) fed 4-month old 
OPN deficient and wild-type adult mice a diet of 0.5% calcium with either 0.16% or 0.6% 
phosphorus for four weeks. OPN deficiency prevented a reduction in bone mineral density 
and mass, changes in trabecular bone patterns, and cortical bone appearance and area, cross-
section, periosteal circumference, and thickness. Bone formation was not affected by OPN 
deficiency, but the bone resorption response to a high phosphorus diet was prevented. Thus, 
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the impact of a high phosphorus diet appears to be mediated in part by both OPN and PTH 
to increase bone resorption.
High dietary phosphorus also adversely affects bone mass accrual during growth. Huttunen 
et al. (33) fed 1-month-old rats diets of 0.6% calcium and either 0.6%, 1.2%, or 1.8% 
phosphorus for 8 weeks. The highest phosphorus diets (1.2% and 1.8%) reduced body 
weight, bone mineral content, and areal bone mineral density. Femur length and PTH were 
lowered at 1.8% P, and dose dependent decreases of trabecular area, width, and perimeter, 
and increases of osteoblast perimeter, osteoclast number, and mineral apposition rate were 
observed. pQCT in the distal metaphysis and midshaft showed a reduced BMC and total 
cross-sectional area, and tibia material properties were reduced on a high phosphorus diet.
Table 1 summarizes human clinical intervention studies on the impact of high dietary 
phosphorus intake and bone and mineral metabolism. Most studies show that high dietary 
phosphorus increases PTH (34–46), and exceptions tend to be studies where dietary calcium 
intake also increased with higher dietary phosphorus intake (41, 47, 48). The effects on bone 
turnover markers is more mixed, but when effects are seen they are generally in the direction 
of increased bone resorption and/or decreased bone formation with higher dietary 
phosphorus. Observational studies exploring the relationship between high dietary 
phosphorus and bone endpoints have similarly found mixed results. In large population 
surveys of the U.S. (49) and South Korea (50), generally no relationships between dietary 
phosphorus and BMD, BMC, or osteoporosis were observed. Similarly, in perimenopausal 
women there tended to be no relationship between dietary phosphorus intake and BMD and 
BMC (but higher dietary calcium and calcium:phosphorus (Ca:P) ratio was positively related 
to BMD and BMC) (51). In contrast, in a Brazilian cohort with low average calcium intake 
(~400 mg/d), for each increase of 100 mg/d in dietary phosphorus there was a 9% increase 
in fracture risk (52). Recently, a combined analysis of the relationship between serum 
phosphate and fracture risk in the Rotterdam Study and MrOS prospective cohorts was 
reported by Campos-Obando et al. (53). Serum phosphate was positively related to fracture 
risk, where there was a 47% increased risk of fracture with each 1 mg/dL increase in serum 
phosphate after adjusting for multiple covariates. Dietary phosphorus intake was available 
for a subset of subjects from MrOS, assessed by food frequency questionnaire. In these 
subjects, fasting serum phosphate did not relate to dietary phosphorus intake, nor did 
adjustment for dietary phosphorus intake affect the association between serum phosphate 
and fracture risk. However, as the authors also note, fasting serum phosphate is less sensitive 
to dietary phosphorus compared to postprandial serum phosphate measures. Additionally, 
accurate assessment of dietary phosphorus intake from food frequency questionnaires is 
limited by participant errors as well as incomplete and inaccurate nutrient database content 
(15). Campos-Obando et al. (53) also note that the increased fracture risk associated with 
serum phosphate was observed within the normal range for serum phosphate, which may 
suggest that usual intakes are too high. However, whether dietary phosphorus intake affects 
serum phosphate levels within the normal range remains unclear.
Recently, Katsumata et al. (54) investigated the effects of high dietary phosphorus bone and 
mineral metabolism-related gene expression in younger (12-week-old) and older (80-week-
old) mice. Mice were fed a diet of either 0.3% or 1.2 % phosphorus, with adequate calcium 
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(0.5%) for four weeks. Serum PTH increased in both young and old mice in response to the 
high phosphorus diet, but to a greater extent in the old mice. Femur RANKL mRNA was 
increased with high dietary phosphorus in both younger and older mice, but the 
RANKL:OPG mRNA ratio was only increased in the old mice, suggesting that the effects of 
high dietary phosphorus on bone resorption are more pronounced with aging. In a second 
study, Katsumata et al. (55) further investigated the effects and interaction between high 
dietary calcium and phosphorus on bone outcomes in rats. Rats were fed either adequate 
calcium (0.5%) or high calcium (1.0%) and either adequate phosphorus (0.3%) or high 
phosphorus (1.5%) in a 2×2 factorial design. High phosphorus diets caused increases in 
PTH, CTX, osteocalcin, and femur RANKL mRNA, and decreases in femur, tibial, and 
lumbar BMD and BMC. High calcium with high phosphorus blunted the effects of the high 
phosphorus diet on PTH, CTX, BMD and BMC measures, and prevented the rise in 
osteocalcin. The Ca:P intake ratio and its relevance in bone health is discussed below.
Dietary Calcium-to-Phosphorus Ratio
Intake of phosphorus relative to calcium is of interest, as these mineral interact in the 
gastrointestinal tract to limit absorption of the other, are intimately related in tissue (e.g. 
hydroxyapatite) and in their hormonal regulation. A 1:1 molar ratio of Ca:P (or ~1.3:1 mass 
ratio Ca mg:P mg) has been recommended to optimize calcium and phosphorus nutrition for 
bone health, yet the vast majority (~90%) of U.S. Americans fall below this ratio due to the 
combination of prevalent low calcium intakes and excessive phosphorus intakes (4). 
However, the current IOM DRI report for phosphorus, published in 1997 (1), made the case 
that the dietary Ca:P ratio was not physiologically relevant in human health within the range 
of dietary phosphorus intakes typically consumed in the U.S. Studies that show associations 
or effects of low Ca:P ratio on bone metabolism are confounded by low calcium intake 
coinciding with the low Ca:P ratio. Additionally, classic balance studies in adults have 
shown that high phosphorus intake does not influence calcium balance or absorption 
compared with low phosphorus intake, and the level of calcium intake does not modulate 
this effect (56–58). And a cross-sectional analysis of 215 young women found no evidence 
for an ideal Ca:P ratio to optimize bone mass (59). However, 20 years since the IOM report, 
the importance of dietary Ca:P ratio for bone health in humans is still unclear and somewhat 
controversial (60, 61). Minimally, it appears that dietary Ca:P ratio has to be taken in context 
of the absolute levels of each mineral in the diet as well (7). However, it is also possible that 
the ratio is irrelevant, but that low dietary calcium and excess dietary phosphorus can each 
be independently harmful to bone. Further, the interaction between low dietary calcium and 
excess dietary phosphorus doesn’t necessarily support the existence of a meaningful ratio 
independent of the absolute values of each nutrient. Nonetheless, high dietary phosphorus 
has consistently shown adverse effects on bone-related outcomes in animal studies, and there 
is human data that also supports an independent effect of high phosphorus intake on adverse 
bone-related outcomes, although less consistently. In recent years, there has been mounting 
evidence that shows adverse effects on bone metabolism with increased phosphorus intake 
from inorganic phosphate additives, which are absorbed rapidly at a high rate.
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Phosphate Additives Effects on Bone Metabolism
Inorganic phosphate additives are highly bioaccessible, as discussed above, and have been 
shown to contribute a substantial amount of phosphorus to total intake in the U.S. (62, 63). 
Cola is a unique source of additive inorganic phosphate that has been studied over the years 
in its effect on bone health. Cola delivers a load of phosphoric acid that is absorbed readily 
and rapidly and is often consumed between meals. A 20 fl. oz. bottle of cola, for example, 
provides 55 mg of phosphorus, whereas non-cola sodas are phosphate-free. In addition, cola 
may displace milk in the diet, so it can contribute to lower calcium intake concurrent along 
with greater inorganic phosphosphates intake (12). This has been investigated in early and 
later life stages. Wyshak (13, 14) observed that higher cola consumption has been associated 
with greater fracture risk in adolescent boys and girls. Tucker et al. (8) found an association 
between greater cola intake and low bone mineral density in older women in the 
Framingham Osteoporosis Study, but no association with non-cola carbonated beverages. 
This supported prior studies in rats that showed impaired bone mineralization and 
hyperparathyroidism when rats were given cola in place of water (9, 10). However, human 
observational studies have not consistently shown these associations between cola intake and 
bone outcomes. There was no association between any type of carbonated beverage 
consumption and bone mineral density in older women who participated in the Rancho 
Bernardo Study (11), nor in the men in the Framingham Osteoporosis Study (8), and 
McGartland et al. (64) found an inverse relationship between non-cola and total carbonated 
beverage consumption in Irish adolescent girls, but no relationship with cola consumption. It 
seems likely that any potential negative effects of cola on bone when it substitutes for milk 
in the diet would be driven by decreased calcium intake and other bone health nutrients (e.g. 
protein, vitamin D) in milk, rather than the difference in phosphorus load. This is because 
milk has about ten times the phosphorus content of cola by volume, so even if we assume 
most liberally that 100% of inorganic phosphate from cola is absorbed and only 40–70% of 
organic phosphorus from milk, this would still result in ~4–7 times more phosphorus 
absorbed from the same volume of milk as cola. However, it may be that the additional 
inorganic phosphate from cola may provide an additional insult to the replacement of 
nutrient-rich milk in the diet.
A recent study by Gutiérrez et al. (65) further evaluated the impact of dietary inorganic 
phosphate additives on bone in complementary studies in humans and mice. Participants in 
the human study were given a “low additive” diet for one week (~1000 mg/d phosphorus), 
followed by an “additive enhanced” diet for one week (~1600 mg/d phosphorus), with ~700 
mg/d of calcium throughout the two week study. After one week on the additive enhanced 
diet, participants had higher FGF23, osteopontin, and osteocalcin, and lower sclerostin and 
P1NP. Similarly, mice fed low (0.2%) and high (1.8%) dietary phosphorus higher FGF23, 
osteopontin, and osteocalcin, lower sclerostin and also lower BMD and unfavorable changes 
in cortical and cancellous bone geometry by μCT. This study is notable as it shows that diets 
high in foods containing inorganic phosphate additives at levels typical in the U.S. can 
adversely alter bone and mineral metabolism.
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Special Considerations for Dietary Phosphorus in CKD-MBD
Dietary phosphorus intake is of particular importance in patients with chronic kidney disease 
(CKD), who develop the co-morbid condition of mineral bone disorder (CKD-MBD). CKD-
MBD is characterized by biochemical abnormalities related to bone and mineral 
metabolism, including elevated serum FGF23, PTH, phosphate, and decreased serum 1,25D 
and calcium; renal osteodystrophy presenting with a range of abnormalities in bone 
mineralization, volume, and/or turnover; and increased vascular calcifications. Patients with 
CKD-MBD have elevated risk for bone fragility fractures, cardiovascular events, and death 
(71, 72). Patients are often prescribed low phosphorus diets as a component of treatment to 
slow or prevent CKD-MBD, hyperparathyroidism, or hyperphosphatemia. But, low 
phosphorus diets are extremely difficult for patients to follow, due to the widespread 
presence of phosphorus in the food supply, other concurrent nutrient and fluid restrictions, 
and while attempting to consume adequately high energy and protein. Thus, there has been 
growing interest in diet liberalization to improve patients’ nutrition and quality of life (73). 
A potential way to limit phosphorus intake in CKD patients without sacrificing overall 
nutrition and quality of life is to focus interventions at limiting non-nutritive or low-nutritive 
phosphate sources. Phosphates coming from medications and from inorganic phosphate 
additives are prime targets for this. Patients with CKD have a high pill burden. Up until 
recently, the phosphate burden from these patients’ medications was unquantified. Nelson et 
al. (74) evaluated the phosphate content of medications prescribed in hemodialysis patients 
with advanced CKD. 11% of drug formulations prescribed in the 101 hemodialysis patients 
in the study contained phosphate, and 30% of patients were taking at least one of these 
medications. The average phosphate burden from prescription medications in this study was 
111 mg/d. This shows that in the context of an 800–1000 mg/d dietary phosphorus 
restriction (75), on average over 10% of recommended intake could be coming from 
medications alone. This knowledge could potentially lead to changes in prescribing practices 
or formulations to reduce phosphate content, but the impact will need to be further 
evaluated.
In 2009, Sullivan et al. (76) published results from a randomized controlled trial aimed at 
reducing intake of phosphate additives. Two-hundred seventy-nine patients at 14 
hemodialysis centers who had serum phosphate ≥ 5.5 mg/dL were randomized by shift to 
receive either usual care plus diet education on how to avoid phosphate additives while 
grocery shopping or at fast food restaurants or usual care alone. At the end of the three 
month intervention, patients in the diet intervention group had significantly greater decline 
(by 0.6 mg/dL) in serum phosphate compared with the usual care control group. There is 
now an additional study (77) newly published in 2017 that supports the conclusions of 
Sullivan. de Fornasari et al. (77) conducted a similar study in 134 hemodialysis patients at a 
single dialysis center who had serum phosphate ≥ 5.5 mg/dL were randomized to receive a 
similar educational intervention to avoid phosphate additives for three months, or usual care. 
Results showed that a significantly greater proportion of the intervention group achieved 
serum phosphate ≤ 5.5 mg/dL (69.7% of patients) compared with only 18.5% of control 
patients at the end of the three month study. The average reduction in serum phosphate was 
1.8 mg/dL greater in the intervention group compared with the control group. Furthermore, 
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this reduction in serum phosphate with the intervention occurred while indices of nutritional 
status including serum albumin, normalized protein nitrogen appearance, body mass index, 
tricep skin fold thickness, and arm muscle area remained unchanged and no different 
between intervention and control at the end of the study. The results of these studies are 
encouraging, and should be followed with longer term studies to evaluate the effects of 
limiting phosphate additives, alone or in combination therapy, on improvement of CKD-
MBD outcomes including fractures, cardiovascular disease, and mortality.
Conclusions
Phosphorus is widespread in our food supply as both natural organic forms and in added 
inorganic forms, and humans have a high efficiency for dietary phosphorus absorption. 
Therefore, phosphorus deficiencies are rare and most people easily meet the RDAs of 700 
mg/d for most adults and 1250 mg/d during adolescent growth. Instead, excess dietary 
phosphorus intake is observed in nearly all age groups in the U.S. Adverse effects of high 
dietary phosphorus on bone health have been observed in bone animal and human studies, 
mediated through elevated PTH and increased OPN. The impact of high dietary phosphorus 
intakes on bone health appears to be compounded by prevalent low calcium intakes in the 
U.S. However, the case for an optimal Ca:P ratio independent of the absolute values of each 
nutrient is relatively weak. Further research is needed on the effectiveness of lowering 
dietary phosphorus intake on fracture risk. However, based on current evidence, a prudent 
approach would be to limit intake of phosphate additives. Phosphorus from plant based 
sources remain less bioavailable than animal sources and animal sources less bioavailable 
compared to inorganic phosphate additives. Additionally, phosphate additives are unrelated 
to foods’ protein content, unlike most naturally-occurring phosphorus in food. So, limiting 
consumption of inorganic phosphate additives is a strategic way to decrease phosphorus 
intake without affecting protein intake (77), which is particularly important for patients with 
CKD on dialysis. At minimum, inclusion of phosphorus content on food labels, and the 
quantification of phosphorus from inorganic phosphate food additives would be helpful for 
those seeking to limit their phosphorus intake (4, 7, 15, 17, 63, 78–80).
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